Stable CHO Cell Pool and Cell Line Development
Large-scale production of recombinant antibodies and proteins
Transient gene expression in mammalian cells provides reasonable amounts of recombinant proteins and antibodies which is sufficient for most applications. Nevertheless, when it comes to bulk productions for in vitro diagnostics or pre-clinical studies for biopharmaceutical development, the required amount of biological material often exceeds the yield that can be obtained through transient approaches. In this case, production from stable cell lines is highly advantageous since it allows easy generation of larger quantities of recombinant proteins and antibodies in measures of up to several grams per batch.
However, developing a stable cell line can be a time and resource intensive process with several bottlenecks that need to be overcome in order to ensure a good yield output.
After years of optimization work to counteract these bottlenecks, InVivo successfully established a proprietary platform for the development of stable cell lines using CHO (Chinese hamster ovary) cells as expression system.
We chose a well-established, cGMP-banked CHO cell line and combined it with our optimized cell culture processes using a high-performance, chemically-defined, animal component-free medium.
Novel expression vectors compatible to the PiggyBac system – a well-established tool for transposon-mediated active gene transfer, were designed. Using these customized vectors, high protein yields and a substantially reduced timeline from transfection to stable CHO cell pools could be achieved.
To further increase product yield, high cell-density fermentation processes were established.
All these combined with a highly optimized process for the selection of best-producing cell pools and screening for high-producing monoclonals, lead to cost-optimized production of target proteins in large quantities.
We understand that every project is unique. Therefore, the entire process can be individually tailored to fit your specific requirements. After detailed rounds of discussion with our scientific experts, we help you decide if a stable cell line needs to be developed or if we can produce the required protein yields from a stable cell pool. With your final go, we start right away.
Production from stable cell pools
In many cases, sufficient material can be obtained through production from stable CHO cell pools instead of going all the way to produce a stable cell line. This approach is beneficial especially for time-sensitive projects, as recombinant antibodies and proteins become available within just a few weeks’ time. During stable transfection, the DNA of interest is integrated into the genome of the host cell to allow steady production of the target protein. However, the location and number of DNA insertions vary from cell to cell. This creates a pool of cells which all express the same protein or antibody, but with varying degrees of expression efficiency. When developing a stable cell line, the resulting cell pool then serves as starting point for single cell cloning and various screening processes, in which the clone with the highest productivity is identified and selected as basis for the stable cell line. By skipping the lengthy screening procedures and continuing with production directly from the cell pool, it is possible to reduce the costs and timeline of your project without compromising on the quality of the product.
Further examples for when to consider a stable cell pool
Rescue a poorly performing hybridoma cell line
When you use monoclonal antibodies from hybridoma cell lines that do not promise the expected yields, then this does not have to be the end of your project. Some hybridoma lines simply do not show the desired productivity or maybe loose it over time. In such cases, it is beneficial to switch to a recombinant approach and produce the antibody of interest in stable CHO cell pools.
First, we in order to generate the relevant constructs for stable expression in CHO cells. Within just a few weeks, you receive the first samples of your recombinant antibody for testing.
Antibody engineering is a fantastic method to optimize antibodies and specifically tailor them for research and downstream applications. Besides sequence optimizations, which potentially lead to higher product yields or higher antibody specificity, also antibody subclass switches can easily be performed as well as generation of chimeric, humanized antibodies. To obtain these custom modified antibodies in large quantities and quick turnaround times, production in stable CHO cells is ideal and highly recommended.
The development of biopharmaceuticals is very costly and production capacity in GMP facilities is often limited. To circumvent this problem and speed up research and development, a large part of the pre-clinical studies can be carried out using InVivo’s CHO cell pool concept based on a well-established cGMP-banked cell line, which can later be transferred into GMP facilities.
By using material from stable cell pools to characterize and evaluate potential drug candidates, it is possible to further reduce timeline and costs whilst optimizing the opportunity to process several of such potential targets in parallel.
Stable Cell Line Development
Stable Cell Development
DNA-design and cloning
Based on customer reference sequence, the target DNA is designed, optimized and synthesized, followed by cloning into InVivo’s proprietary expression vector. DNA preparation occurs using a sustainable and optimized in-house process to win excellent transfection grade plasmid DNA.
The expression vector is introduced into CHO cells via PEI-mediated transfection. Through transposon-mediated active gene transfer, the target DNA is stably inserted in the host cell genome.
~ 1 week
Selection of stable expressors
To select for pools with stable expression of the target DNA, double selection with puromycin and MTX is performed. The pools with best productivity are chosen and secured.
Selection of best pool
Small-scale test productions with the generated cell pools are performed. Productivity is determined by analytical chromatography, and the best producing cell pool is identified.
Single Cell Cloning
The selected cell pool is used for limited dilution to isolate monoclones. Clonality screening occurs with the NyONE FL10 imager; productivity is measured by analytical biolayer interferometry (Octet) and chromatography. Up to 3 monoclones are selected and expanded.
The best producing cell pool is used for upscaling productions dependent on customer requirements (fed-batch shaker assay or fed-batch fermentation in bioreactor).
Clone stability testing
The selected clone is cultivated over 60-70 population doublings and the clone expression stability is evaluated by analytical chromatography
The best monoclone is used for upscaling productions dependent on customer requirements (fed-batch shaker assay or fed-batch fermentation in bioreactor).
Production from stable cell lines
If large amounts of recombinant antibodies or proteins are required in the long term, for example for the production of immunoassays for in-vitro diagnostics, then it is advisable to develop a stable cell line for subsequent productions. Starting from a selected stable cell pool, single cell cloning via limited dilution is performed and 100 monoclones are selected to undergo a multistep-screening process in order to identify 3 high-producer clones. In consultation with the customer, a final clone is selected to form the stable cell line. As stability of a cell line is very crucial, we perform clone stability testing to assure stable expression over time. Therefore, the selected monoclones are monitored over 60-70 population doublings and productivity is measured via biolayer interferometry (Octet) and analytical chromatography. This ensures that the final cell line produces the desired product reliably in large-scale for all future productions.
InVivo’s highly optimized platform is based on proprietary expression vectors, high quality medium and perfectly harmonized processes. This ensures cost-efficient production with highest product yields at reduced processing times.
Every project is unique. Therefore, we offer maximum flexibility when it comes to project design, production scale and product specifications. So, at the end, you get exactly what you need.
We are ISO9001 and ISO13485 certified and our aim is to achieve excellent quality for all products manufactured at InVivo – every single time with highest purity and perfect batch-to-batch consistency.
We ensure fully confidential data protection for every project. The intellectual property of the final product lies with you and only you decide if, when and who else gets to access it.
We guarantee regular project updates and include you into all important decisions along the entire development cascade. Test samples of your product can be shared with every important milestone that we reach, so that you are able to decide on how to proceed.
At InVivo, we produce under non-GMP conditions, therefore no license fees apply and there are no other hidden costs. We only charge for the service we provide. After a cell line or cell pool has been developed, for all subsequent productions, you only pay for the ordered amount of the final product.
Cost-efficient production through implemented equipment and well-defined processes.
If desired, we adapt our standard processes to your favored protocol.
Only you decide who else gets access to your product.
Rely on our longstanding expertise.
We include you to all important decisions along the entire development process.
No royalties. After completion of cell line development, you only pay for the ordered amount of final product.
Invivo Biotech Services